Pipeline · Lead Candidate
BFRx3711
A novel, in-house-engineered long-acting GLP-1 analog, positioned for potential once-monthly subcutaneous administration in obesity and type 2 diabetes — designed to compete for the convenience segment beyond today's once-weekly therapies.
- Once-monthly
- Dosing ambition (SQ)
- ~420–450 hr
- Projected human half-life (~18 days)
- 2.7×
- Minipig half-life vs. semaglutide
- 19%
- Weight reduction, DIO mice (day 16)
Design & Mechanism
Engineered for a differentiated GLP-1 profile
BFRx3711 is a short peptide — under 40 amino acids — engineered to extend duration of action while preserving the receptor activity that defines the GLP-1 class.
Engineered for stability & duration
Company-designed GLP-1 peptide modifications target improved DPP-4 and other enzyme resistance and stronger albumin binding — the basis for the molecule's extended in vivo half-life.
Semaglutide-like receptor activity
CRE-Luc / GLP1R / HEK293 assays showed GLP-1R activation potency comparable to semaglutide, with Tag-Lite FRET demonstrating dose-dependent receptor binding both with and without 2% HSA.
Materially extended PK
In rats, PK parameters were superior to semaglutide and tirzepatide. In minipigs, half-life was approximately 2.7× semaglutide — supporting a projected 420–450 hour human half-life.
Encouraging safety signal
BFRx3711 did not show GCGR receptor activation in cAMP testing, which management interprets as supportive of a lower standalone hypoglycemia risk.
Preclinical Efficacy
Competitive efficacy with extended PK
Anti-obesity efficacy
In DIO mouse studies, 28-day body-weight and food-consumption effects were similar to semaglutide, including a 19% body-weight reduction by day 16.
Diabetes signal
Non-fasted glucose remained below 5 mmol/L for 4 days in DIO mice, versus 2 days for semaglutide in the company's comparative study.
Figures reflect company preclinical studies. Detailed data — including full receptor pharmacology, PK, and in vivo results — are available to qualified partners under NDA.
Competitive Positioning
Whitespace between weekly leaders and monthly challengers
Weekly injectables dominate GLP-1 economics today. BFRx3711 is being developed to compete for the emerging convenience segment, where less-frequent dosing may improve differentiation, compliance, and strategic value.
| Program | Status | Dosing | Takeaway |
|---|---|---|---|
| BFRx3711Ours | Preclinical / IND-track | Potential monthly SQ | Projected ~420–450 hr human half-life with preclinical efficacy comparable to semaglutide in company studies. |
| Semaglutide (Ozempic / Wegovy) | Commercial | Weekly SQ / daily oral | Established GLP-1 class benchmark in type 2 diabetes and obesity. |
| Tirzepatide (Mounjaro / Zepbound) | Commercial | Weekly SQ | Established dual-incretin benchmark with strong commercial momentum. |
| MET-097i | Phase 2b | Monthly target | Monthly GLP-1 comparator referenced in company materials. |
| MariTide | Phase 2 | Monthly potential | High-dose formulation requirements may create injection-volume challenges. |
BFRx3711's shorter peptide profile (under 40 amino acids) may support a simpler regulatory and manufacturing path relative to longer-peptide comparators. Comparator details reflect company materials.
Development Roadmap
A defined path with multiple value-inflection points
- 12026
Preclinical / IND-enabling work begins
- 2Q3 2027
FDA IND meeting
- 3Q3 2028
Phase 1 complete
- 4Q3 2030
Phase 2 complete
- 52033
Phase 3 complete & NDA filing
- 6Q4 2034
Approval & commercial launch
BioFutureRx has the option to complete Phase 1 and then license the program to a larger partner for later-stage development and commercialization. The full development budget and financial model are available under NDA.
A large, durable category
$200B+
Industry forecasts place the total GLP-1 market for obesity and type 2 diabetes in the hundreds of billions of dollars and still expanding — with obesity representing the larger share. A differentiated, less-frequent dosing option is a compelling position within it.
Intellectual property
Composition-of-matter protection to 2045
BFRx3711 is covered by patent protection through 2045, with potential patent term extension of up to five years, and additional filings anticipated. Full patent details are disclosed under NDA.
Confidential Materials
Request the BFRx3711 teaser & data package
The full investor teaser, preclinical data package, long-range financial model, and the identity of the asset and originating company are shared with qualified partners under a non-disclosure agreement. Contact us to begin a confidential discussion.
Forward-looking statements: This page contains forward-looking statements regarding a product candidate in development. Preclinical results are not necessarily predictive of clinical outcomes, and there is no guarantee that BFRx3711 will achieve the results described or obtain regulatory approval. Projected half-life, timelines, market sizes, and other forward-looking figures are company estimates and should be independently diligenced. “BFRx3711” is a placeholder designation; the actual product and company identities are disclosed only under a non-disclosure agreement. Nothing on this page is an offer to sell or a solicitation of an offer to buy any security.